First-line management of advanced non-small-cell lung cancer: can we do better?

被引：0
|
作者：
Chouaid, Christos [1 ,2 ]
Monnet, Isabelle [1 ]
Auliac, Jean-Bernard [1 ]
机构：
[1] CHI Creteil, Serv Pneumol, Creteil, France
[2] UPEC, Inserm U955, IMRB, Creteil, France
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2023年 / 12卷 / 07期
关键词：
Lung cancer; immunotherapy; management; chemotherapy; NSCLC; ATEZOLIZUMAB; CHEMOTHERAPY; PHASE-3; PD-L1; IMMUNOTHERAPY; ASSOCIATION; COMBINATION; SURVIVAL; PLATINUM;
D O I：
10.21037/tlcr-23-200
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1643 / 1648
页数：6
相关论文
共 50 条
  • [1] First-line treatment for advanced non-small-cell lung cancer
    Laskin, Janessa J.
    Sandler, Alan B.
    [J]. ONCOLOGY-NEW YORK, 2005, 19 (13): : 1671 - 1676
  • [2] First-line immunotherapy in advanced non-small-cell lung cancer
    Noronha, Vanita
    Mehta, Prashant
    Malik, Prabhat Singh
    Patel, Amol
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 461 - 462
  • [3] Oxaliplatin in First-line Therapy for Advanced Non-Small-Cell Lung Cancer
    Raez, Luis E.
    Kobina, Svetlana
    Santos, Edgardo S.
    [J]. CLINICAL LUNG CANCER, 2010, 11 (01) : 18 - 24
  • [4] First-Line Immunotherapy for Non-Small-Cell Lung Cancer
    Reck, Martin
    Remon, Jordi
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 586 - +
  • [5] Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer
    Heigener, David F.
    Kerr, Keith M.
    Laing, Gavin M.
    Mok, Tony S. K.
    Moiseyenko, Fedor V.
    Reck, Martin
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (16) : 4881 - 4887
  • [6] Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Gettinger, Scott
    Rizvi, Naiyer A.
    Chow, Laura Q.
    Borghaei, Hossein
    Brahmer, Julie
    Ready, Neal
    Gerber, David E.
    Shepherd, Frances A.
    Antonia, Scott
    Goldman, JonathanW.
    Juergens, Rosalyn A.
    Laurie, Scott A.
    Nathan, Faith E.
    Shen, Yun
    Harbison, Christopher T.
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2980 - +
  • [7] Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer
    Socinski, M. A.
    [J]. CURRENT ONCOLOGY, 2014, 21 (05) : E691 - E703
  • [8] First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer
    Lin, Jessica J.
    Gainor, Justin F.
    [J]. LANCET RESPIRATORY MEDICINE, 2023, 11 (04): : 302 - 304
  • [9] First-line treatment of advanced ALK-positive non-small-cell lung cancer
    Gandhi, Shipra
    Chen, Hongbin
    Zhao, Yujie
    Dy, Grace K.
    [J]. LUNG CANCER-TARGETS AND THERAPY, 2015, 6 : 71 - 82
  • [10] Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
    Hayashi, H.
    Okamoto, I.
    Morita, S.
    Taguri, M.
    Nakagawa, K.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (06) : 1537 - 1541
12345